Tomofumi Ando

Tomofumi Ando

Auto-generated profile, based on publicly available information

Tomofumi Ando

Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2024 in Cancer Immunology Research
Verified
Journal Article
Open access
SMSatoru Morita
Satoru Morita
PLPin-Ji Lei
Pin-Ji Lei
KSKohei Shigeta
Kohei Shigeta
TATomofumi Ando
Tomofumi Ando
TKTATSUYA KOBAYASHI
TATSUYA KOBAYASHI
Dan G DudaDan G Duda
Dan G Duda
Immune checkpoint inhibitors have revolutionized the treatment of unresectable hepatocellular carcinoma (HCC), but their impressive efficacy is seen in just a fraction of patients. One key mechanism of immunotherapy resistance is the paucity of dendritic cells (DC) in liver malignancies. In this study, we tested combination blockade of PD-1 and CXCR4, a receptor for CXCL12, a pleiotropic factor that mediates immunosuppression in tumors. Using orthotopic grafted and autochthonous HCC models with underlying liver damage, we evaluated treatment feasibility and efficacy. In addition, we examined the effects of treatment using immunofluorescence, flow cytometric analysis of DCs in vivo and in vitro, and RNA sequencing. The combination anti-CXCR4 and anti–PD-1 therapy was safe and significantly inhibited tumor growth and prolonged survival in all murine preclinical models of HCC tested. The combination treatment successfully reprogrammed antigen-presenting cells, revealing the potential role of conventional type 1 DCs (cDC1) in the HCC microenvironment. Moreover, DC reprogramming enhanced anticancer immunity by facilitating CD8+ T-cell accumulation and activation in the HCC tissue. The effectiveness of anti-CXCR4/PD-1 therapy was compromised entirely in Batf3 knockout mice deficient in cDC1s. Thus, combined CXCR4/PD-1 blockade can reprogram intratumoral cDC1s and holds the potential to potentiate antitumor immune response against HCC.

7 February 2023 in Annals of Gastroenterological Surgery
Verified
Journal Article
Open access
SOSoji Ozawa
Soji Ozawa
YUYusuke Uchi
Yusuke Uchi
TATomofumi Ando
Tomofumi Ando
KHKoki Hayashi
Koki Hayashi
TATakuma Aoki
Takuma Aoki
In this review, we focused on four topics, namely, minimally invasive esophagectomy (MIE), robot‐assisted minimally invasive esophagectomy (RAMIE), conversion and salvage surgery, and neoadjuvant and adjuvant therapy, based on notable reports published in the years 2020 and 2021. It seems that while the short‐term outcomes of minimally invasive Ivor Lewis esophagectomy (MIE‐IL) were better than those of open Ivor Lewis esophagectomy (OE‐IL), there were no significant differences in the long‐term outcomes between MIE‐IL and OE‐IL. Similarly, the short‐term outcomes of minimally invasive McKeown esophagectomy (MIE‐MK) were better than those of open McKeown esophagectomy (OE‐MK), while there were no significant differences in the long‐term outcomes between MIE‐MK and OE‐MK. Furthermore, the short‐term outcomes of robot‐assisted minimally invasive Ivor Lewis esophagectomy (RAMIE‐IL) were superior to those of completely minimally invasive Ivor Lewis esophagectomy (CMIE‐IL). On the other hand, there were advantages and disadvantages in relation to the short‐term outcomes of robot‐assisted minimally invasive McKeown esophagectomy (RAMIE‐MK) as compared with completely minimally invasive McKeown esophagectomy (CMIE‐MK). However, there were no significant differences in the long‐term outcomes between RAMIE‐MK and CMIE‐MK. Further research is needed to evaluate of short‐term and long‐term outcomes of transmediastinal esophagectomy with and without robotic assistance. Both induction chemotherapy and induction chemoradiotherapy appear to be promising to secure a higher rate of conversion surgery. Neoadjuvant chemoimmunotherapy and chemoimmunoradiotherapy have shown promising results and are expected as new powerful therapies.

1 November 2021 in Journal of Surgical Research
Verified
Journal Article
Closed access
TATomofumi Ando
Tomofumi Ando
TOTaishu Oka
Taishu Oka
GOGo Oshima
Go Oshima
KHKan Handa
Kan Handa
SMShingo Maeda
Shingo Maeda
SASatoshi Aiko
Satoshi Aiko

8 December 2025 in Nature Communications
Verified
Journal Article
Open access
XLXin Liu
Xin Liu
ZLZelong Liu
Zelong Liu
CZChengzhan Zhu
Chengzhan Zhu
TKTatsuya Kobayashi
Tatsuya Kobayashi
PLPin-Ji Lei
Pin-Ji Lei
Dan G DudaDan G Duda
Dan G Duda
Most patients with hepatocellular carcinoma (HCC) develop resistance to immune checkpoint blockade (ICB) or STING agonists despite their immune-stimulating activities. Here, we identify increased intratumoral B-cell infiltration as a mediator of acquired resistance. In HCC models with liver fibrosis in male mice, anti-PD-1 ICB or the STING agonist BMS-986301 increase intratumoral B-cell infiltration, circulating IL-10, and TIM-1+ B-cells, promoting tertiary lymphoid structure formation. B-cell depletion combined with ICB or STING agonism improves survival, and STING agonism inhibits distant metastasis. In addition, co-targeting STING and TIM-1 enhances B-cell differentiation and antigen presentation, reduces intratumoral TIM-1+ B-cells, and increases CD86 and MHC class II expression, thereby augmenting CD8+ T-cell-mediated anti-tumor immunity. These findings reveal that B-cells contribute to ICB and STING therapy resistance in HCC, and that B-cell depletion or TIM-1 blockade can overcome acquired resistance to these immunotherapies.

3 February 2025
Verified
Other
Open access
SMSatoru Morita
Satoru Morita
PLPin-Ji Lei
Pin-Ji Lei
KSKohei Shigeta
Kohei Shigeta
TATomofumi Ando
Tomofumi Ando
TKTATSUYA KOBAYASHI
TATSUYA KOBAYASHI
Dan G DudaDan G Duda
Dan G Duda
Immune checkpoint inhibitors have revolutionized the treatment of unresectable hepatocellular carcinoma (HCC), but their impressive efficacy is seen in just a fraction of patients. One key mechanism of immunotherapy resistance is the paucity of dendritic cells (DC) in liver malignancies. In this study, we tested combination blockade of PD-1 and CXCR4, a receptor for CXCL12, a pleiotropic factor that mediates immunosuppression in tumors. Using orthotopic grafted and autochthonous HCC models with underlying liver damage, we evaluated treatment feasibility and efficacy. In addition, we examined the effects of treatment using immunofluorescence, flow cytometric analysis of DCs in vivo and in vitro, and RNA sequencing. The combination anti-CXCR4 and anti–PD-1 therapy was safe and significantly inhibited tumor growth and prolonged survival in all murine preclinical models of HCC tested. The combination treatment successfully reprogrammed antigen-presenting cells, revealing the potential role of conventional type 1 DCs (cDC1) in the HCC microenvironment. Moreover, DC reprogramming enhanced anticancer immunity by facilitating CD8+ T-cell accumulation and activation in the HCC tissue. The effectiveness of anti-CXCR4/PD-1 therapy was compromised entirely in Batf3 knockout mice deficient in cDC1s. Thus, combined CXCR4/PD-1 blockade can reprogram intratumoral cDC1s and holds the potential to potentiate antitumor immune response against HCC.

3 February 2025
Verified
Other
Open access
SMSatoru Morita
Satoru Morita
PLPin-Ji Lei
Pin-Ji Lei
KSKohei Shigeta
Kohei Shigeta
TATomofumi Ando
Tomofumi Ando
TKTATSUYA KOBAYASHI
TATSUYA KOBAYASHI
Dan G DudaDan G Duda
Dan G Duda
Figure S7 from Combination CXCR4 and PD-1 Blockade Enhances Intratumoral Dendritic Cell Activation and Immune Responses Against Hepatocellular Carcinoma